Belmont, Lisa D.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine

Cell death mechanisms and regulationCancer-related Molecular Pathways

Cited by 541

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

Wilson, C., Ye, X., Pham, T., Lin, E., Chan, S., McNamara, E., Neve, R. M., Belmont, L., Koeppen, H., Yauch, R. L., et al. (2014) · Cancer Research

Cancer Cells and MetastasisLung Cancer Treatments and Mutations

Cited by 150

Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations

Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology

Chronic Lymphocytic Leukemia ResearchProtein Degradation and Inhibitors

Cited by 137

The STARD9/Kif16a Kinesin Associates with Mitotic Microtubules and Regulates Spindle Pole Assembly

Torres, J. Z., Summers, M. K., Peterson, D., Brauer, M. J., Lee, J., Senese, S., Gholkar, A. A., Lo, Y.-C., Lei, X., Jung, K., et al. (2011) · Cell

Microtubule and mitosis dynamicsCancer Treatment and Pharmacology

Cited by 80